About

Adora Ndu, Pharm.D., J.D., has served as an ACADIA director since October 2022. She is Chief Regulatory Officer and Executive Vice President of Portfolio Strategy and Management at BridgeBio Pharma, which she joined in 2022, and previously held regulatory leadership roles at BioMarin Pharmaceutical and served in various roles at the U.S. Food and Drug Administration from 2008 to 2016, most recently as a Division Director in the Division of Medical Policy Development. She currently serves on the board of DBV Technologies. She earned her Pharm.D. from Howard University and her J.D. from the University of Maryland.

Roles

Acadia Pharmaceuticals Inc.
Director · Current role
October 2022–present
BridgeBio Pharma Inc.
Chief Regulatory Officer & EVP, Portfolio Strategy and Management
October 2024 - present
BridgeBio Pharma Inc.
Chief Regulatory and Interim Legal Officer
October 2022 - September 2023
BridgeBio Pharma Inc.
Chief Regulatory Affairs Officer
January 2022 - present
BioMarin Pharmaceutical Inc.
Group Vice President, Worldwide R&D Strategy, Scientific Collaborations and Policy
January 2021 - January 2022
U.S. Food and Drug Administration
Division Director, Division of Medical Policy Development (various roles)
2008 - 2016

External Roles

DBV Technologies S.A.
Director

Director Compensation

FY 2025
Fees earned or paid in cash
$43,199
ComponentAnnual Board and committee cash retainers earned in FY2025
Option awards
$176,392
ComponentAnnual stock option grant, ASC 718 grant-date fair value
Stock awards
$180,705
ComponentAnnual restricted stock unit grant, ASC 718 grant-date fair value
Total
$400,294

Also at Acadia Pharmaceuticals Inc.

Related

See how VectorShift works for your firm

Request Demo